CY1113030T1 - Αντιβιοτικο 107891, παραγοντες του, φαρμακευτικως αποδεκτα αλατα και συνθεσεις και η χρηση τους - Google Patents

Αντιβιοτικο 107891, παραγοντες του, φαρμακευτικως αποδεκτα αλατα και συνθεσεις και η χρηση τους

Info

Publication number
CY1113030T1
CY1113030T1 CY20121100727T CY121100727T CY1113030T1 CY 1113030 T1 CY1113030 T1 CY 1113030T1 CY 20121100727 T CY20121100727 T CY 20121100727T CY 121100727 T CY121100727 T CY 121100727T CY 1113030 T1 CY1113030 T1 CY 1113030T1
Authority
CY
Cyprus
Prior art keywords
antibiotic
factors
compositions
activity against
resistant
Prior art date
Application number
CY20121100727T
Other languages
English (en)
Inventor
Ameriga Lazzarini
Luciano Gastaldo
Gianpaolo Candiani
Ismaela Ciciliato
Daniele Losi
Flavia Marinelli
Enrico Selva
Franco Parenti
Original Assignee
Sentinella Pharmaceuticals, Inc. ("Sentinella")
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sentinella Pharmaceuticals, Inc. ("Sentinella") filed Critical Sentinella Pharmaceuticals, Inc. ("Sentinella")
Publication of CY1113030T1 publication Critical patent/CY1113030T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Η εφεύρεση αφορά σε μια αντιβιοτική ουσία μικροβιακής προέλευσης, αυθαίρετα ονομασμένη αντιβιοτικό 107891 που παράγεται από τη ζύμωση του Microbispora sp. ATCC ΡΤΑ-5024, τα φαρμακευτικώς αποδεκτά άλατα και τις συνθέσεις τους και στη χρήση τους ως ένα αντιβακτηριακό παράγοντα που έχει ανασταλτική δραστικότητα ενάντια στα ευαίσθητα μικρόβια. Το αντιβιοτικό 107891 που είναι ένα σύνθετο που περιλαμβάνει δύο Παράγοντες, που ονομάζονται Παράγοντες Α1 και Α2, έχει δομή πεπτιδίου που περιέχει λανθειονίνη και μεθυλολανθειονίνη ως συστατικά που είναι τυπικά χαρακτηριστικά των αντιβιοτικών της ομάδας των λαντιβιοτικών. Το αντιβιοτικό 107891 και οι Παράγοντές του Α1 και Α2 παρουσιάζουν καλή αντιβακτηριακή δραστικότητα ενάντια στα γκραμ θετικά βακτηρίδια συμπεριλαμβανομένων των ανθεκτικών σε μεθικιλλίνη και ανθεκτικών σε βανκομυκίνη στελεχών και είναι δραστικοί επίσης ενάντια σε μερικά γκραμ αρνητικά βακτηρίδια όπως τα είδη Μ. catharralis και Neisseria και Η. influenzae και τα μυκοβακτήρια.
CY20121100727T 2005-01-26 2012-08-13 Αντιβιοτικο 107891, παραγοντες του, φαρμακευτικως αποδεκτα αλατα και συνθεσεις και η χρηση τους CY1113030T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/045,628 US7351687B2 (en) 2003-07-18 2005-01-26 Antibiotic 107891, its factors A1 and A2, pharmaceutically acceptable salts and compositions, and use thereof
EP05712250A EP1848731B1 (en) 2005-01-26 2005-01-27 Antibiotic 107891, its factors, pharmaceutically acceptable salts and compositions, and use thereof

Publications (1)

Publication Number Publication Date
CY1113030T1 true CY1113030T1 (el) 2016-04-13

Family

ID=36740829

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100727T CY1113030T1 (el) 2005-01-26 2012-08-13 Αντιβιοτικο 107891, παραγοντες του, φαρμακευτικως αποδεκτα αλατα και συνθεσεις και η χρηση τους

Country Status (26)

Country Link
US (1) US7351687B2 (el)
EP (2) EP2402366A1 (el)
JP (1) JP4191238B2 (el)
KR (1) KR100896826B1 (el)
CN (1) CN101189252B (el)
AU (1) AU2005326149C1 (el)
BR (1) BRPI0519942A2 (el)
CA (1) CA2593801A1 (el)
CY (1) CY1113030T1 (el)
DK (1) DK1848731T3 (el)
EA (1) EA016608B1 (el)
ES (1) ES2387557T3 (el)
HR (1) HRP20120634T1 (el)
IL (1) IL184377A0 (el)
MA (1) MA29237B1 (el)
MX (1) MX2007009059A (el)
NO (1) NO20073490L (el)
NZ (1) NZ556368A (el)
PL (1) PL1848731T3 (el)
PT (1) PT1848731E (el)
RS (1) RS52427B (el)
SI (1) SI1848731T1 (el)
TN (1) TNSN07286A1 (el)
UA (1) UA87548C2 (el)
WO (1) WO2006080920A1 (el)
ZA (1) ZA200705495B (el)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0600928D0 (en) 2006-01-17 2006-02-22 Novacta Biosystems Ltd Improvements relating to lantibiotics
GB0714029D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd Lantibiotic-based compounds having antimicrobial activity
GB0714030D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd The use of type-B lantibiotic-based compounds having antimicrobial activity
CA2749278A1 (en) 2009-01-14 2010-07-22 Novacta Biosystems Limited Deoxyactagardine derivatives
KR20110122139A (ko) 2009-02-04 2011-11-09 노박타 바이오시스템스 리미티드 액타가르딘 유도체
GB201001688D0 (en) 2010-02-02 2010-03-17 Novacta Biosystems Ltd Compounds
GB201013513D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Formulations
US11174288B2 (en) 2016-12-06 2021-11-16 Northeastern University Heparin-binding cationic peptide self-assembling peptide amphiphiles useful against drug-resistant bacteria

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59198982A (ja) 1983-04-28 1984-11-10 Meiji Seika Kaisha Ltd 新抗生物質ｓｆ−２２４０物質およびその製造法
EP0592835A3 (en) 1992-09-23 1995-03-15 Bristol Myers Squibb Co Antibiotics of type BU-4803T.
US6551591B1 (en) 2001-09-07 2003-04-22 Essential Therapeutics, Inc. Antibiotics from microbispora
US6551581B1 (en) 2001-12-27 2003-04-22 Avon Products, Inc. Methods for improving the aesthetic appearance of skin and hair
ES2281808T3 (es) * 2003-07-18 2007-10-01 Vicuron Pharmaceuticals, Inc. Antibiotico 107891, sus factores a1 y a2, composiciones y sales farmaceuticamente aceptables y uso del mismo.
WO2006075988A1 (en) * 2005-01-12 2006-07-20 Vicuron Pharmaceuticals Inc. Antibiotic 107891, its factors a1 and a2, pharmaceutically acceptable salts and compositions, and use thereof
RS52513B (en) * 2005-01-12 2013-04-30 Sentinella Pharmaceuticals Inc. ("Sentinella") ANTIBIOTIC 107891, ITS FACTORS, PHARMACEUTICALALLY ACCEPTABLE SALTS AND MIXTURES, AND THEIR USE
UA87546C2 (ru) * 2005-01-12 2009-07-27 Найконс С.К.А.Р.Л Антибиотик 107891, его факторы а1 и а2, фармацевтически приемлемые соли, композиция и их использование

Also Published As

Publication number Publication date
EP1848731A4 (en) 2008-11-12
EP1848731A1 (en) 2007-10-31
EP2402366A1 (en) 2012-01-04
CN101189252A (zh) 2008-05-28
NZ556368A (en) 2010-09-30
AU2005326149A1 (en) 2006-08-03
HRP20120634T1 (hr) 2012-08-31
CA2593801A1 (en) 2006-08-03
UA87548C2 (ru) 2009-07-27
MX2007009059A (es) 2008-02-12
SI1848731T1 (sl) 2012-09-28
NO20073490L (no) 2007-08-07
EA200701384A1 (ru) 2008-02-28
IL184377A0 (en) 2007-10-31
CN101189252B (zh) 2012-07-18
EP1848731B1 (en) 2012-05-23
PT1848731E (pt) 2012-08-20
US20050233952A1 (en) 2005-10-20
RS52427B (en) 2013-02-28
AU2005326149B2 (en) 2009-10-29
US7351687B2 (en) 2008-04-01
EA016608B1 (ru) 2012-06-29
MA29237B1 (fr) 2008-02-01
TNSN07286A1 (fr) 2008-12-31
DK1848731T3 (da) 2012-09-03
KR100896826B1 (ko) 2009-05-12
PL1848731T3 (pl) 2012-10-31
KR20070090043A (ko) 2007-09-04
AU2005326149C1 (en) 2010-04-01
ZA200705495B (en) 2008-12-31
ES2387557T3 (es) 2012-09-26
JP4191238B2 (ja) 2008-12-03
JP2008528581A (ja) 2008-07-31
BRPI0519942A2 (pt) 2009-04-07
WO2006080920A1 (en) 2006-08-03

Similar Documents

Publication Publication Date Title
CY1113030T1 (el) Αντιβιοτικο 107891, παραγοντες του, φαρμακευτικως αποδεκτα αλατα και συνθεσεις και η χρηση τους
CN102871996B (zh) 一种抗菌药物组合物及其应用
RU95101039A (ru) Антибиотические производные гликопептидов, способ получения, фармацевтическая композиция
RU2011130278A (ru) Новые противобактериальные средства для лечения грамположительных инфекций
WO2005070945A8 (ja) メチシリン耐性黄色ブドウ球菌（ｍｒｓａ）に有効な新規アミノグリコシド系抗生物質
MXPA06000691A (es) Antibiotico 107891, sus factores a1 y a2, sales y composiciones farmaceuticamente aceptables y uso de las mismas.
JP2012513467A5 (el)
AR073917A1 (es) Sinergismo antibiotico
Abraham et al. A tick antivirulence protein potentiates antibiotics against Staphylococcus aureus
CY1113157T1 (el) Αντιβιοτικο 107891, παραγοντες του, φαρμακευτικως αποδεκτα αλατα και συνθεσεις και η χρηση τους
AR039727A1 (es) Difluorotioacetamidas de oxazolidinonas como agentes antibacterianos y composicion farmaceutica en base a ellas
WO2004098500A3 (en) CARBACEPHEM ss-LACTAM ANTIBIOTICS
Mattina et al. In vitro activity of a new quinolone, rufloxacin, against nosocomial isolates
EA200701267A1 (ru) Антибиотик 107891, его факторы а1 и а2, фармацевтически приемлемые соли и композиции и их применение
Oli et al. Actinomycetes in Medical and Pharmaceutical Industries
ATE295852T1 (de) Antibiotische tripropeptine und verfahren ihrer herstellung
Mar Soe et al. Ethyl gallate as a combination drug can overcome resistance in MRSA
Yoshida et al. Potent in vitro bactericidal activity of polymyxin B against methicillin-resistant Staphylococcus aureus (MRSA)
Sader et al. In vitro activity and potency of the novel oxazolidinone MRX-I tested against contemporary clinical isolates of Gram-positive bacteria
Prasetyoputri et al. Antibiotic potentiators to combat resistance in methicillin-resistant Staphylococcus aureus (MRSA): A mini review
Sader et al. Update on Daptomycin Activity and Spectrum When Tested Against Gram-Positive Strains Collected in European Medical Centers (2006)
Thakur et al. Antimicrobial resistance in gram positive and gram negative bacteria progress and challenges
BR0214494A (pt) Fatores antibióticos ge 81112 a, b, b1, seus sais e composições farmaceuticamente aceitáveis e uso dos mesmos
Abraham et al. 1 A tick antivirulence protein potentiates antibiotics against Staphylococcus aureus 2
JOSHI et al. In vitro evaluation of antibacterial activity of a novel polyenzyme preparation Immunoseb